As Sanofi is set to launch its injectable antibody drug to prevent respiratory syncytial virus (RSV) lower respiratory tract disease for the first time in South Korea, the company begins marketing.

The company aims to raise awareness of RSV disease to promote vaccination. Sanofi has strategized a top-down approach, starting with labor and delivery hospitals, and expanding to private practices. As clinical practices have high demand for the vaccine, it is likely to enter the market quickly.

According to industry sources on August 6th, Sanofi is set to launch Beyfortus, an injectable antibody for RSV prevention, ahead of the upcoming 2024-2025 vaccination season.

Be